Accessibility Menu
Spruce Biosciences logo

Spruce Biosciences(NASDAQ) SPRB

Current Price$44.48
Market Cap$125.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-96%
5 Year-94%
1 Year+396%
1 Month-18%
Spruce Biosciences last closing stock price
MetricPriceDate
Last closeUSD 44.602026-07-22
Spruce Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.85%USD 45.442026-07-15
1 month-18.46%USD 54.702026-06-22
3 month-17.42%USD 54.012026-04-23
Year to date-48.8%USD 87.112025-12-31
1 year+395.56%USD 9.002025-07-22
3 year-73.21%USD 166.502023-07-21
5 year-93.77%USD 716.252021-07-23
Since inception-96.42%USD 1,275.002020-10-09

Spruce Biosciences Financials at a Glance

Market Cap

$125.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$37.19M

EPS (TTM)

-$37.70

P/E Ratio

-1.21

Dividend

$0.00

Beta (Volatility)

1.33 (Average)

Price

$44.48

Volume

38,284.824

Open

$45.27

Previous Close

$44.60

Daily Range

$44.16 - $45.28

52-Week Range

$7.00 - $240.00

Estimated Earnings Date

Aug 13, 2026

SPRB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spruce Biosciences

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focusing on developing innovative therapies for rare endocrine disorders. Their lead product, tildacerfont, is designed to address classic congenital adrenal hyperplasia (CAH), a condition with significant unmet medical needs. The company aims to transform the treatment paradigm for this and other rare diseases by providing non-steroidal treatment options.

Products and Services

Tildacerfont: An oral antagonist targeting the CRF1 receptor, currently in clinical trials for classic congenital adrenal hyperplasia (CAH).

POWER Study: Clinical trials exploring the application of tildacerfont in polycystic ovary syndrome (PCOS).

Strategic collaborations for expanded therapeutic applications worldwide.

What Makes Spruce Biosciences, Inc. Special

Spruce Biosciences differentiates itself through a strategic focus on rare endocrine disorders, a niche with high unmet needs and limited competition. By leveraging deep expertise in endocrine diseases, the company aims to deliver novel therapies faster and more efficiently. Their leadership team brings substantial experience and strategic vision, further setting them apart in the biopharmaceutical sector.

Five Things You Need to Know

Spruce's primary candidate, tildacerfont, targets rare and serious conditions like classic CAH.

The company operates in a niche market with limited competition, focusing on rare endocrine disorders.

Spruce has secured orphan drug designation, enabling potential market exclusivity if approved.

Strategic partnerships, such as with Kaken Pharmaceutical in Japan, expand therapeutic reach.

Experienced leadership with a background in successful drug development and commercialization.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Javier Szwarcberg, MD

Website

sprucebio.com

Headquarters

South San Francisco, CA 94014, US

SPRB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-155.40%

Return on Capital

-84.42%

Return on Assets

-66.22%

Earnings Yield

-82.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$125.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.75M

Volume

38.28K

Avg. Volume

67.59K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$34.01M

EBITDA

-$36.20M

Operating Cash Flow

-$29.33M

Capital Expenditure

-$10.00K

Free Cash Flow

-$29.34M

Cash & ST Invst.

$54.08M

Total Debt

$7.12M

Spruce Biosciences Performance Analysis

Spruce Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 10,089,000N/A
20242024-12-31USD 4,911,000-51.3%
20252025-12-31USD 0N/A
Spruce Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Spruce Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -147.218.4%
20232023-12-31USD -93.32-36.6%
20242024-12-31USD -96.393.3%
20252025-12-31USD -50.83-47.3%
Spruce Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3085.8%
Q32025-09-30-327.6%
Q42025-12-3126.8%
Q12026-03-3116.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$125.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.29M

N/A

Employees

20

N/A

Net Income

-$12.27M

+12.6%

EBITDA

-$11.34M

+19.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$54.08M

+111.1%

Total Debt

$7.12M

+210.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.80M

+779.5%

Short Term Debt

$1.33M

-18.9%

Return on Assets

-66.22%

N/A

Return on Invested Capital

-76.63%

N/A

Free Cash Flow

-$8.74M

+31.3%

Operating Cash Flow

-$8.73M

+31.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EQEquillium, Inc.
$2.76+4.94%
CUECue Biopharma, Inc.
$34.20+2.21%
VTVTvTv Therapeutics Inc.
$31.67-3.77%
NRXPNRx Pharmaceuticals, Inc.
$4.48+0.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%
NOKNokia
$10.28-0.03%

Questions About SPRB

What is the current price of Spruce Biosciences?

Spruce Biosciences is trading at $44.60 per share.

What is the 52-week range for Spruce Biosciences?

Over the past 52 weeks, Spruce Biosciences has traded between $7.00 and $240.00.

How much debt does Spruce Biosciences have?

As of the most recent reporting period, Spruce Biosciences reported total debt of $7.12M.

How much cash does Spruce Biosciences have on hand?

Spruce Biosciences reported $54.08M in cash and cash equivalents in its most recent financial results.

What is Spruce Biosciences’s dividend yield?

Spruce Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services